COMMUNIQUÉS West-GlobeNewswire

NTG Nordic Transport Group A/S invites to Capital Markets Day on November 18, 2026
05/05/2026
NTG Nordic Transport Group – Capital Markets Day 2026 We would like to invite institutional investors and analysts to attend our Capital Markets Day on 18 November 2026. A detailed programme will follow, but please mark [...]
Valneva publiera ses résultats financiers consolidés du premier semestre le 13 mai 2026
05/05/2026
Lyon (France), le 5 mai 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers du premier semestre le mercredi 13 mai [...]
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
05/05/2026
Lyon (France), May 05, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The [...]
IBA SA – NOTIFICATION TRANSPARENCE
05/05/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 5 mai 2026 – 18h Résumé de la notification IBA (Ion Beam Applications SA), le [...]
IBA – TRANSPARENCY NOTIFICATION
05/05/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, May 5th, 2026 – 6 p.m. Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
VALNEVA : Déclaration d’actions et de droits de vote - Statut au 30 avril 2026 tenant compte d’informations intermédiaires au 5 mai 2026
05/05/2026
VALNEVA Déclaration d’actions et de droits de vote Statut au 30 avril 2026 tenant compte d’informations intermédiaires au 5 mai 2026 [...]
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
05/05/2026
VALNEVA Declaration of shares and voting rights Status as of April 30, 2026 taking into account interim information as at May 5, 2026 [...]
IBA – ACQUISITION D’ACTIONS PROPRES
05/05/2026
Louvain-la-Neuve, Belgique, 5 mai 2026 – 18h30 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique [...]
IBA – ACQUISITION OF OWN SHARES
05/05/2026
Louvain-la-Neuve, Belgium, May 5 th , 2026 – 6:30 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
05/05/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound [...]
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
05/05/2026
PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non- [...]
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
05/05/2026
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction [...]
Geron Plans to Present at Upcoming Investor Conferences
05/05/2026
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
05/05/2026
Overall, studies show: OGM Can Resolve Previously Unresolved Rare Disease Cases OGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV Sensitivity and Genomic [...]
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
05/05/2026
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO [...]
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
05/05/2026
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of [...]
Clene to Present at Upcoming May Conferences
05/05/2026
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company [...]
PathAI and A.C.Camargo Cancer Center Announce Cooperation to Expand Digital Pathology with AI in Brazil via SUS
05/05/2026
Collaboration supports national digital pathology transformation initiatives and broadens access to AI-enabled oncological diagnostics BOSTON and SÃO PAULO, May 05, 2026 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI [...]
Transplants.org Launches as Centralized Education and Navigation Platform for Organ and Stem Cell Transplant Patients
05/05/2026
New nonprofit simplifies the transplant journey with clinician-backed guidance and transparent outcomes data WASHINGTON, May 05, 2026 (GLOBE NEWSWIRE) -- Transplants.org , a 501(c)(3) nonprofit organization, today [...]

Pages